Evaluating OBI-833/OBI-821 with Erlotinib for Lung Cancer
A Randomized, Open-Label, Phase 2 Study to Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study is testing if adding two new treatments, OBI-833 and OBI-821, to the standard lung cancer drug erlotinib can help people with a specific type of lung cancer feel better and live longer.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | OBI Pharma, Inc Industry-sponsored |
| Drugs / interventions | rituximab, alemtuzumab, natalizumab, erlotinib, chemotherapy, Immunotherapy, cyclophosphamide |
| Locations | 7 sites (Taipei, Beitou District and 6 other locations) |
| Trial ID | NCT05442060 on ClinicalTrials.gov |
What this trial studies
This phase 2 trial investigates the efficacy of OBI-833 and OBI-821 in combination with erlotinib in patients with EGFR-mutated, Globo H-positive non-small cell lung cancer (NSCLC). Eligible participants, who have achieved stable disease or partial response after 3 months of erlotinib treatment, will be randomized to receive either erlotinib alone or the combination therapy. The study will monitor humoral immune responses and follow patients for survival outcomes for up to 12 months after treatment. The trial aims to assess the potential benefits of adding OBI-833 and OBI-821 to standard erlotinib therapy.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20 and older with EGFR-mutated, Globo H-positive NSCLC who have shown stable disease or partial response after initial erlotinib treatment.
Not a fit: Patients without EGFR mutations or those who have not achieved stable disease or partial response after erlotinib treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this combination therapy could improve treatment outcomes for patients with advanced NSCLC.
How similar studies have performed: While similar approaches have been explored, this specific combination of OBI-833/OBI-821 with erlotinib in this patient population is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Aged ≥ 20 years.
2. Pathologically or cytologically confirmed diagnosis of non-small cell lung cancer whose stage is IIIB, IIIC, IVA, or IVB according to the AJCC Cancer Staging System, 8th Edition.
3. The tumor harbors an exon 19 deletion or exon 21 L858R mutation in EGFR, confirmed locally.
4. Patient must have a documented Globo H H-score of at least 100 using a validated central IHC assay.
5. Patient must have received 3±1 months of first-line erlotinib therapy under a stable dosage of 150 mg/day, have achieved SD or PR before randomization (as confirmed by the Investigator), and plan to continue the erlotinib treatment at 150 mg/day.
6. At least one measurable tumor lesion according to RECIST version 1.1 as assessed by the Investigator (local radiological image assessment).
7. Life expectancy ≥ 6 months.
8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
9. Organ Function Requirements - Subjects must have adequate organ functions as defined below:
* AST/ALT ≤ 3X ULN (upper limit of normal); AST/ALT ≤ 5X ULN in the presence of liver metastases
* Total bilirubin ≤ 2.0 X ULN
* Serum creatinine ≤ 1.5X ULN
* ANC ≥ 1,500 /µL
* Platelets ≥ 100,000/µL
10. All eligible patients of childbearing potential must use effective contraception during study treatment, and for at least 2 months after the last dose of OBI-833/OBI-821 and for at least 2 weeks after the last dose of erlotinib. Subjects not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in the study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.
11. Understand and provide a written informed consent document according to institutional guidelines.
Exclusion Criteria:
1. Patient who has CNS metastasis.
2. Patient who is pregnant or breast-feeding at entry.
3. Patient with splenectomy.
4. Patient with HIV infection, active hepatitis B infection, or active hepatitis C infection.
5. Patient with a positive test result for SARS-CoV-2 detected by standard reverse transcription-polymerase chain reaction (RT-PCR) at screening.
6. Patient with any autoimmune or other disorders requiring IV/oral steroids or immunosuppressive or immunomodulatory therapies.
(e.g., type 1 juvenile onset diabetes mellitus, antibody positive for rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, Crohn disease, ulcerative colitis, and psoriasis).
7. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.
8. A history of other malignancies (except non-melanoma skin carcinoma, carcinoma in situ of the uterine cervix, follicular or papillary thyroid cancer) within 5 years prior to randomization.
9. Patient with any known uncontrolled comorbid illness including ongoing or active infections, symptomatic congestive heart failure (NYHA\>2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
10. Treatment with any of the following therapies within 4 weeks prior to randomization:
* Anti-cancer therapies, including chemotherapy and targeted therapy (except erlotinib).
* Radiotherapy.
* Immunotherapy, including monoclonal antibodies, cytokines, interferons, and checkpoint inhibitors.
* Immunosuppressants, including cyclosporin, rapamycin, tacrolimus, rituximab, alemtuzumab, natalizumab, and cyclophosphamide.
* Other biologics, including G-CSF and other hematopoietic growth factors.
* Live attenuated vaccines.
* IV/oral steroids except single prophylactic use in CT/MRI scan or other one-time use in approved indications. Use of inhaled and topical (except on the injection site) steroids is allowed.
* Alternative and complementary medicine that may affect the immune system.
* Other investigational drugs.
11. Subject with pleural effusions and/or ascites, due to malignancy, requiring paracentesis every 2 weeks or more frequently.
12. Subject with any known severe allergies (e.g., anaphylaxis) to any active or inactive ingredients in the study drugs.
13. Any other reason that the investigator deems the patient to be unsuitable for the study.
Where this trial is running
Taipei, Beitou District and 6 other locations
- Taipei Veterans General Hospital — Taipei, Beitou District, Taiwan (Recruiting)
- National Taiwan University Cancer Center — Taipei, Da'an Dist., Taiwan (Recruiting)
- Linkou Chang Gung Memorial Hospital — Taoyuan, Guishan Dist., Taiwan (Recruiting)
- Tri-Service General Hospital — Taipei, Neihu District, Taiwan (Recruiting)
- Shuang Ho Hospital — New Taipei City, Zhonghe District, Taiwan (Recruiting)
- National Taiwan University Hospital — Taipei, Zhongzheng Dist., Taiwan (Recruiting)
- Taichung Veterans General Hospital — Taichung, Taiwan (Recruiting)
Study contacts
- Study coordinator: Anna Hu
- Email: annahu@obipharma.com
- Phone: 886-2-27866589
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.